IP Library Granted Patent US 7,205,105
Granted Patent B2
US 7,205,105 · App. 10/165,410 · Granted Apr 17, 2007

Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis

Assignee: Epoch Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,205,105
App. No.
10/165,410
Granted
Apr 17, 2007
Kind
B2
Abstract

Oligonucleotide probes/conjugates are provided along with method for their use in assays to monitor amplification wherein the signal produced does not rely on 5′ nuclease digestion.

Claims (11)

1. A method for distinguishing between wild-type, mutant and heterozygous target polynucleotides, said method comprising:

(a) contacting a sample containing a target polynucleotide with two probes wherein a first probe is specific for said wild-type target polynucleotide and a second probe is specific for said mutant target polynucleotide, each of said probes having a formula:

wherein MGB is a minor groove binder, Q is a quencher, W is a trivalent linking group, ODN is an oligonucleotide or modified oligonucleotide, K is a bond or a linking group and Fl is a fluorophore; wherein said first and second probes have different fluorophores and each of said probes forms a stable hybrid only with the target sequence that is perfectly complementary to the ODN portion of said probes; and

(b) measuring the fluorescence produced on hybrid formation for each fluorophore, wherein said measuring is carried out at two wavelengths and is measured as a function of temperature, and using melting curve analysis to indicate the presence or absence of each of said wild-type, mutant and heterozygous target polynucleotides.

2. A method in accordance with claim 1 , wherein the melting temperatures (T m ) for each hybrid produced between said first and second probes and their respective targets are within about 5° C. of each other.

3. A method in accordance with claim 1 , wherein the ODN portion of each of said probes is an oligonucleotide or modified oligonucleotide having from 8 to 18 bases or modified bases.

4. A method in accordance with claim 1 , wherein the ODN portion of each of said probes is an oligonucleotide or modified oligonucleotide having from 10 to 15 bases or modified bases.

5. A method in accordance with claim 1 , wherein the fluorophore portions of each of said probes are selected from the group consisting of 5-FAM™, 6-FAM™, TET™, JOE™, HEX™, VIC™, NED™, TAMRA™, ROX™and YY™.

6. A method in accordance with claim 1 , wherein the ODN portion of each of said probes contains at least one modified base.

7. A method in accordance with claim 6 , wherein each modified base is independently selected from the group consisting of 6-amino-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 4-amino-1H-pyrazolo[3,4-d]pyrimidine, 1H-pyrazolo[5,4-d]pyrimidin-4(5H)-6(7H)-dione, 6-amino-3-prop-1-ynyl-5-hydropyrazol[3,4-d]pyrimidine-4-one, 6-amino-3-(3-hydroxyprop-1-ynyl)1-5-hydropyrazolo[3,4-d]pyrimidine-4-one, 6-amino-3-(3-aminoprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidine-4-one, 4-amino-3-(prop-1-ynyl)pyrazolo[3,4-d]pyrimidine, 4-amino-3-(3-hydroxyprop-1-ynyl)pyrazolo[3,4-d]pyrimidine, 4-amino-3-(3-aminoprop-1-ynyl)pyrazolo[3,4-d]pyrimidine, 3-prop-1-ynyl-4,6-diaminopyrazolo[3,4-d]pyrimidine, 2-(4,6-diaminopyrazolo[3,4-d]pyrimidin-3-yl)ethyn-1-ol, 3-(2-aminoethynyl)pyrazolo[3,4-d]pyrimidine-4,6-diamine, 5-prop-1-ynyl-1,3-dihydropyrimidine 2,4-dione, 5-(3-hydroxyprop-1-ynyl)-1,3-dihydropyrimidine-2,4-dione, 6-amino-5-prop-1-ynyl-3-dihydropyrimidine-2-one, 6-amino-5-(3-hydroxyprop-1-ynyl)-1,3-dihydropyrimidine-2-one, 6-amino-5-(3-aminoprop-1-ynyl)-1,3 -dihydropyrimidine-2-one, 5-[4-amino-3-(3-methoxyprop-1ynyl)pyrazol[3,4-d]pyrimidinyl]-2-(hydroxymethyl)oxolan-3-ol, 6-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-(3-methoxyprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidin-4-one, 4-(4,6-Diamino-1H-pyrazololl[3,4-d]pyrimidin-3-yl)-but-3-yn-1-ol, 6-Amino-3-(4-hydroxy-but-1-ynyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one, 5-(4-hydroxy-but-1-ynyl)-1H-pyrimidine-2,4-dione, 3-iodo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-bromo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-chioro-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-lodo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine and 3-chioro-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine.

8. A method in accordance with claim 1 , wherein said sample is further contacted with a set of primers under amplification conditions and each of said primers contains from one to ten modified bases selected from the group consisting of 6-amino-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 4-amino-1H-pyrazolo[3,4-d]pyrimidine, 1H-pyrazolo[5,4-d]pyrimidin-4(5H)-6(7H)-dione, 6-amino-3-prop-1-ynyl-5-hydropyrazolo[3,4-d]pyrimidine-4-one, 6-amino-3-(3-hydroxyprop-1-yny)1-5-hydropyrazolo[3,4-d]pyrimidine-4-one, 6-amino-3-(3-aminoprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidine-4-one, 4-amino-3-(prop-1-ynyl)pyrazolo[3,4-d]pyrimidine, 4-amino-3-(3-hydroxyprop-1-ynyl)pyrazolo[3,4-d]pyrimidine, 4-amino-3-(3-aminoprop-1-ynyl)pyrazolo[3,4-d]pyrimidine, 3-prop-1-ynyl-4,6-diaminopyrazolo[3,4-d]pyrimidine, 2-(4,6-diaminopyrazolo[3,4-d]pyrimidin-3-yl)ethyn-1-ol, 3-(2-aminoethynyl)pyrazolo [3,4-d]pyrimidine-4,6-diamine, 5-prop-1-ynyl-1,3-dihydropyrimidine-2,4-dione, 5-(3 -hydroxyprop-1-ynyl)-1,3-dihydropyrimidine-2,4-dione, 6-amino-5-prop-1-ynyl-3-dihydropyrimidine-2-one, 6-amino-5-(3-hydroxyprop-1-ynyl)-1,3-dihydropyrimidine-2-one, 6-amino-5-(3-aminoprop-1-ynyl)-1,3-dihydropyrimidine-2-one, 5-[4-amino-3-(3-methoxyprop-1-ynyl)pyrazol[3,4-d]pyrimidinyl]-2-(hydroxymethyl)oxolan-3-ol, 6-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-(3-methoxyprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidin-4-one, 4-(4,6-Diamino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-but-3-yn-1-ol, 6-Amino-3-(4-hydroxy-but-1-ynyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one, 5-(4-hydroxy-but-1-ynyl) -1H-pyrimidine-2,4-dione, 3-iodo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-bromo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-chloro-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-lodo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine and 3-chioro-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: ELITECHGROUP B.V.
To: ELITECHGROUP, INC.
Reel/Frame 048078/0553 →
CHANGE OF NAME Recorded Mar 10, 2017
From: ELITECH HOLDING BV
To: ELITECHGROUP B.V.
Reel/Frame 041974/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2017
From: EPOCH BIOSCIENCES, INC.
To: ELITECH HOLDING BV
Reel/Frame 041925/0808 →
RELEASE OF SECURITY INTEREST Recorded Feb 26, 2015
From: PORTSIDE GROWTH AND OPPORTUNITY FUND
To: EPOCH BIOSCIENCES, INC.
Reel/Frame 035038/0812 →
GRANT OF SECURITY INTEREST Recorded Feb 17, 2009
From: EPOCH BIOSCIENCES, INC.
To: PORTSIDE GROWTH AND OPPORTUNITY FUND, AS COLLATERAL AGENT
Reel/Frame 022266/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2005
From: AFONINA, IRINA A.; BELOUSOV, YEVGENIY S.; DEMPCY, ROBERT O.; KUTYAVAN, IGOR V.; LOKHOV, SERGEY G.; LUKHTANOV, EUGENY A.
To: EPOCH BIOSCIENCES, INC.
Reel/Frame 016409/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2002
From: BELOUSOV, YEVGENIY S.; AFONINA, IRINA A.
To: EPOCH BIOSCIENCES, INC.
Reel/Frame 013546/0504 →
Continuity (5)
Continuation In Part 0987683000 · Jun 6, 2001
Continuation In Part 0945761600 · Dec 8, 1999
Provisional Application 6035163700 · Jan 23, 2002
Provisional Application 6030213700 · Jun 29, 2001
Related Publication 20030175728A1 · Sep 18, 2003